Advanz pharma and alvotech receive european approval for mynzepli®, biosimilar to eylea®

Reykjavik, iceland and london, uk (august 21, 2025) — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma holdco limited (“advanz pharma”), a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the european commission has approved mynzepli® as a biosimilar to eylea® (aflibercept), in a pre-filled syringe and vial.
ALVO Ratings Summary
ALVO Quant Ranking